Nimorazole - Azanta

Drug Profile

Nimorazole - Azanta

Alternative Names: Nimoral

Latest Information Update: 24 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Azanta
  • Developer Azanta; Danish Head and Neck Cancer Group; European Organisation for Research and Treatment of Cancer; International Atomic Energy Agency; The Christie NHS Foundation Trust
  • Class Antibacterials; Antineoplastics; Antiprotozoals; Nitroimidazoles; Radiation-sensitising agents; Radiosensitisers
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase III Head and neck cancer

Most Recent Events

  • 24 Nov 2016 Phase-III clinical trials in Head and neck cancer (Combination therapy) in Denmark (PO) (NCT02661152)
  • 13 Mar 2015 Nimorazole is available on a Named Patient Access Programme for the treatment of Head and neck cancer worldwide
  • 26 Feb 2015 Nimorazole licensed to Hikma Pharmaceuticals in Middle East and North Africa region, including Turkey
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top